Insight Medical Publishing

Journal of Pharmacological reviews and reports 2020

Vol.0 No.0

# Assessment of Critical DNA Damage Responsible for the Cytotoxicity of Anticancer Drugs

Mahmoud I. Shoulkamy[1, 2], Toshiaki Nakano[3], Xingzhi Xu[1] and Hiroshi Ide

[1] Shenzhen University School of Medicine, China

[2] Minia university, Egypt

[3]Institute for Quantum Life Science, National Institutes of Quantum and Radiological Science and Technology, Japan

[4] Hiroshima university, Japan

## Abstract

Anticancer drugs can concurrently generate three detrimental DNA lesions including DNA double-strand breaks (DSBs), DNA-protein cross-links (DPCs), and interstrand cross-links (ICLs) to varying degrees, and these lesions may differentially contribute to the toxicity of the drugs. However, no systematic studies have been performed about how much individual DSB, DPC, and ICL lesions contribute to cell killing upon treatment with anticancer drugs. Keeping this in mind, we treated HeLa cells with the equitoxic doses (LD20) of anticancer drugs and analyzed the induction of DSBs and DPCs. The association of ICLs with drug toxicity was assessed by the unique sensitivity of Chinese hamster ovary cells deficient in the xeroderma pigmentosum complementation group F gene. The results show that DNA lesions intimately associated with drug cytotoxicity vary significantly when HeLa cells are treated at the physiologically relevant doses. The critical cytotoxic DNA lesions are DSBsand DPCs for topoisomerase inhibitors (camptothecin and etoposide), DPCs for a DNA cytosine methyltransferase inhibitor (2'-deoxy -5-azacytidine), DPCs and ICLs for platinum drugs (cisplatin and oxaliplatin). Interestingly, cytotoxic DNA lesions are different for melphalan and mitomycin Calthough both are bifunctional alkylating agents. DSBs, DPCs, and ICLs are all associated with the cytotoxicity of melphalan, whereas ICLs alone are associated with the cytotoxicity of mitomycin C.Overall, our results provide a critical role of DPCs in anticancer drugs toxicity and raise the impact of DPC as a target for cancer therapies.

## Biography:

Mahmoud IbrahimShoulkamy, PhD. Joined School of Medicine, Shenzhen University, Chinain 2019 as an Associate Research Scientist in Genome Stability & Disease Preventionlab.He also worksas Associate Professor in Minia University, Egypt.He did his Ph.D.in Molecular and Cell Biology (DNA repair)at Hiroshima University in 2013, where he studying the induction and repair of DNA damage induced by various DNA damaging agents. He went on to do his post-doctoral working Gene Chemistry lab, Hiroshima University, where he got3yearsspecial appointed Assistant Professor. His current work investigates the molecular mechanisms and signaling pathways of gastric cancer

## Speaker Publications:

1. Abd El-Aziz T.M.#, Shoulkamy M.I.#, Hegazy A.M., Stockand J.D., Mahmoud A., Mashaly A.M.A. 2019: Comparative study of the in vivo toxicity and pathophysiology of envenomation by three medically important Egyptian snake venoms. Archives of Toxicology, p1-10.(# equal contribution)
2. Ide H, Nakano T, Salem AM and ShoulkamyMI.( 2018) DNA–protein cross-links: formidable challenges to maintaining genome integrity, DNA Repair, 71:190-197.
3. Nakano T, Xu Xu, Salem AM,Shoulkamy MI,Ide H. (2017) Radiation-induced DNA-protein cross-links: Mechanisms and biological significance, Free Radical Biology and Medicine, 107: 136-145.
4. M.Z. Xie, Shoulkamy MI, A.M. Salem, S. Oba, M. Goda, T. Nakano, H. Ide (2016) Aldehydes with high and low toxicities inactivate cells by damaging distinct cellular targets,Journal of Mutation Research786: 41-51.
5. Nakano T., Mitsusada Y., Salem A., Shoulkamy MI.,Sugimoto T., Hirayama R., Uzawa A., Furusawa Y., and Ide H. (2015) Induction of DNA–protein cross-links by ionizing radiation and their elimination from thegenome. Journal of Mutation Research, 771: 45-50.
6. Miyamoto-Matsubara M., Han Y., Ono K., Xie M., Salem A., Shoulkamy MI., Nakano T., and Ide H. (2014) Depletion of RUVBL2 in human cells confers moderatesensitivity to anticancer agents. Journal of Cancer Science & Therapy, 6 (11):433-439.
7. Shoulkamy MI,Nakano T, Ohshima M, Hirayama R, Uzawa A, Furusawa Y, Ide H. (2012) Detection of DNA-protein crosslinks (DPCs) by novel direct fluorescence labeling methods: distinct stabilities of aldehyde and radiation-induced DPCs. Nucleic Acids Research 40(18): e143.

22nd World Congress on Toxicology and Pharmacology, Webinar, July 14-15, 2020.

**Abstract Citation:**

Mahmoud I. Shoulkamy, Assessment of Critical DNA Damage Responsible for the Cytotoxicity of Anticancer Drugs, Toxicology Congress 2020, 22nd World Congress on

Toxicology and Pharmacology; Webinar, June 14-15, 2020 (https://toxicology-pharmacology.conferenceseries.com/abstract/2020/assessment-of-critical-dna-damage-responsible-for-the-cytotoxicity-of-anticancer-drugs)